PCCB

Across TCGA pan-cancer cohorts, PCCB mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated PCCB data layer compared with 20 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in colon adenocarcinoma (COAD), where higher PCCB mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated PCCB expression acts as an unfavorable survival marker, although some lineages such as COAD and PDAC show a favorable association.

COAD, UCEC, and PDAC are the cancer types where PCCB mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
COAD	DFS	Median	II,III,IV	1.000	0.911	.012	66	view →
UCEC	OS	Quartile	II,III,IV	0.415	1.000	.031	16	view →
PDAC	DFS	Quartile	All	0.563	0.209	.007	10	view →
CCRCC	OS	Median	IV	1.000	0.451	.016	1	view →
HNSC	DFS	Median	All	0.565	0.721	.044	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

PCCB–COAD (DFS)

Open the COAD breakdown →